Clinical development of immuno-oncology therapeutics

IF 9.1 1区医学 Q1 ONCOLOGY

Cancer letters Pub Date : 2025-03-06 DOI:10.1016/j.canlet.2025.217616

Jianxin Wang , Qi Chen , qiang Shan , Tingbo Liang , Patrick Forde , Lei Zheng

{"title":"Clinical development of immuno-oncology therapeutics","authors":"Jianxin Wang , Qi Chen , qiang Shan , Tingbo Liang , Patrick Forde , Lei Zheng","doi":"10.1016/j.canlet.2025.217616","DOIUrl":null,"url":null,"abstract":"<div><div>Immuno-oncology (IO) is one of the fastest growing therapeutic areas within oncology. IO agents work indirectly via the host's adaptive and innate immune system to recognize and eradicate tumor cells. Despite checkpoint inhibitors being only introduced to the market since 2011, they have become the second most approved product category. Current Food and Drug Administration (FDA)-approved classes of IO agents include: immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell therapy (CAR-T), bi-specific T-cell engager (BiTE) antibody therapy, T-cell receptor (TCR) engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine therapy, cancer vaccine therapy, and oncolytic virus therapy. Cancer immunotherapy has made progress in multiple cancer types including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and urothelial carcinoma; however, several cancers remain refractory to immunotherapy. Future directions of IO include exploration in the neoadjuvant/perioperative setting, combination strategies, and optimizing patient selection through improved biomarkers.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"617 ","pages":"Article 217616"},"PeriodicalIF":9.1000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525001806","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immuno-oncology (IO) is one of the fastest growing therapeutic areas within oncology. IO agents work indirectly via the host's adaptive and innate immune system to recognize and eradicate tumor cells. Despite checkpoint inhibitors being only introduced to the market since 2011, they have become the second most approved product category. Current Food and Drug Administration (FDA)-approved classes of IO agents include: immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell therapy (CAR-T), bi-specific T-cell engager (BiTE) antibody therapy, T-cell receptor (TCR) engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine therapy, cancer vaccine therapy, and oncolytic virus therapy. Cancer immunotherapy has made progress in multiple cancer types including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and urothelial carcinoma; however, several cancers remain refractory to immunotherapy. Future directions of IO include exploration in the neoadjuvant/perioperative setting, combination strategies, and optimizing patient selection through improved biomarkers.

查看原文本刊更多论文

免疫肿瘤学治疗的临床发展。

免疫肿瘤学是肿瘤学中发展最快的治疗领域之一。IO药物通过宿主的适应性和先天免疫系统间接起作用，以识别和根除肿瘤细胞。尽管检查点抑制剂自2011年才被引入市场，但它们已成为第二大获批的产品类别。目前美国食品和药物管理局（FDA）批准的IO药物类别包括：免疫检查点抑制剂（ICIs）、嵌合抗原受体T细胞疗法（CAR-T）、双特异性T细胞参与器（BiTE）抗体疗法、T细胞受体（TCR）工程T细胞疗法、肿瘤浸润淋巴细胞（TIL）疗法、细胞因子疗法、癌症疫苗疗法和溶瘤病毒疗法。癌症免疫治疗在多种癌症类型中取得了进展，包括黑色素瘤、非小细胞肺癌（NSCLC）、肾细胞癌（RCC）和尿路上皮癌；然而，有几种癌症对免疫疗法仍然难以治愈。IO的未来方向包括探索新辅助/围手术期环境，联合策略以及通过改进生物标志物优化患者选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer letters 医学-肿瘤学

CiteScore

17.70

自引率

2.10%

发文量

427

审稿时长

15 days

期刊介绍： Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research. Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy. By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.